Immunotherapeutic progress and application of bispecific antibody in cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapeutic progress and application of bispecific antibody in cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-10-20
DOI
10.3389/fimmu.2022.1020003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- (2022) Charles C Wykoff et al. LANCET
- Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
- (2022) Alison M Schram et al. Cancer Discovery
- Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG
- (2022) Chihiro Ishiwatari-Ogata et al. Frontiers in Immunology
- Facile discovery of surrogate cytokine agonists
- (2022) Michelle Yen et al. CELL
- Mosunetuzumab: First Approval
- (2022) Connie Kang DRUGS
- Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling
- (2022) Gabriele Hintzen et al. Frontiers in Oncology
- Faricimab: an investigational agent targeting the Tie-2/Angiopoietin pathway and VEGF-A for the treatment of retinal diseases
- (2021) Massimo Nicolò et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.
- (2021) Shubham Pant et al. JOURNAL OF CLINICAL ONCOLOGY
- B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes
- (2021) Gihoon You et al. Science Advances
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia
- (2021) Franco Locatelli et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity
- (2021) Peter Ruf et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2
- (2021) Danesh Hassani et al. Current Research in Translational Medicine
- FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice
- (2021) Henrik Østergaard et al. BLOOD
- Amivantamab: First Approval
- (2021) Yahiya Y. Syed DRUGS
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- (2021) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
- (2021) Daisuke Kamakura et al. Pharmaceuticals
- The BiTE (Bispecific T‐Cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types
- (2020) Hermann Einsele et al. CANCER
- Targeting the ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC
- (2020) Junfei Gu et al. Cell Death & Disease
- Amivantamab (JNJ-61186372), An Fc Enhanced EGFR/cMet Bispecific Antibody Induces Receptor Downmodulation And Anti-tumor Activity By Monocyte/Macrophage Trogocytosis
- (2020) Smruthi Vijayaraghavan et al. MOLECULAR CANCER THERAPEUTICS
- Greatest Hits—Innovative Technologies for High Throughput Identification of Bispecific Antibodies
- (2020) Tim Hofmann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
- (2020) Dong-Hoon Yeom et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bispecific Antibodies in the Treatment of Hematologic Malignancies
- (2019) Johannes Duell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
- (2019) Steven A. Kliewer et al. Cell Metabolism
- Nanobody: outstanding features for diagnostic and therapeutic applications
- (2019) J.-Pablo Salvador et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
- (2019) Anne Månsson Kvarnhammar et al. Journal for ImmunoTherapy of Cancer
- Using bispecific antibodies in forced degradation studies to analyze the structure–function relationships of symmetrically and asymmetrically modified antibodies
- (2019) Adam R. Evans et al. mAbs
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Emicizumab: A Review in Haemophilia A
- (2019) Hannah A. Blair DRUGS
- Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease
- (2019) Rehan M. Hussain et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines
- (2018) MAKOTO KUBO et al. ANTICANCER RESEARCH
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
- (2018) Z. Wu et al. PHARMACOLOGY & THERAPEUTICS
- Tumor angiogenesis and anti‑angiogenic gene therapy for cancer (Review)
- (2018) Tinglu Li et al. Oncology Letters
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
- (2018) Johnny Mahlangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Engineering therapeutic bispecific antibodies using CrossMab technology
- (2018) Christian Klein et al. METHODS
- Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies
- (2017) Dennis R. Goulet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- OX40: Structure and function – What questions remain?
- (2017) Jane Willoughby et al. MOLECULAR IMMUNOLOGY
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors
- (2017) Johannes Oldenburg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- OUP accepted manuscript
- (2017) PROTEIN ENGINEERING DESIGN & SELECTION
- Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
- (2017) Keiko Esaki et al. THROMBOSIS AND HAEMOSTASIS
- Feedback regulation of RTK signaling in development
- (2017) Cynthia L. Neben et al. DEVELOPMENTAL BIOLOGY
- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
- (2016) M. Bacac et al. CLINICAL CANCER RESEARCH
- Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
- (2016) Matthias Klinger et al. IMMUNOLOGICAL REVIEWS
- Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
- (2016) Maria-Elisabeth Goebeler et al. LEUKEMIA & LYMPHOMA
- Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis
- (2016) Dongheon Lee et al. mAbs
- Systematic review of the role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic targets?
- (2016) Gerdie M. de Jong et al. MALARIA JOURNAL
- Coming-of-Age of Antibodies in Cancer Therapeutics
- (2016) B. Vijayalakshmi Ayyar et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
- (2016) Michael Frogel JOURNAL OF MANAGED CARE PHARMACY
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Bispecific antibodies and their applications
- (2015) Gaowei Fan et al. Journal of Hematology & Oncology
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies
- (2015) Gerhard Zugmaier et al. MOLECULAR IMMUNOLOGY
- The role of amyloid-beta in the regulation of memory
- (2014) John E. Morley et al. BIOCHEMICAL PHARMACOLOGY
- Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system
- (2014) Yiren Xu et al. mAbs
- Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
- (2014) Steven M Lewis et al. NATURE BIOTECHNOLOGY
- Bispecific antibodies rise again
- (2014) Ken Garber NATURE REVIEWS DRUG DISCOVERY
- Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
- (2014) Ulrich H. Weidle et al. SEMINARS IN ONCOLOGY
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- (2013) D. T. Teachey et al. BLOOD
- Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release
- (2013) David Eastwood et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- (2013) Y. Kienast et al. CLINICAL CANCER RESEARCH
- Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule
- (2013) Clarissa G. Jakob et al. mAbs
- Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
- (2012) Christian Klein et al. mAbs
- World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA
- (2012) Eugen Dhimolea et al. mAbs
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
- (2012) Takehisa Kitazawa et al. NATURE MEDICINE
- Blinatumomab: A historical perspective
- (2012) Dirk Nagorsen et al. PHARMACOLOGY & THERAPEUTICS
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
- (2011) Dirk Nagorsen et al. EXPERIMENTAL CELL RESEARCH
- HGF-independent potentiation of EGFR action by c-Met
- (2011) A M Dulak et al. ONCOGENE
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
- (2011) W. Schaefer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
- (2011) Y. J. Yu et al. Science Translational Medicine
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
- (2010) Syd Johnson et al. JOURNAL OF MOLECULAR BIOLOGY
- Bispecific antibodies for cancer therapy
- (2010) Patrick Chames et al. mAbs
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- Review of catumaxomab in the treatment of malignant ascites
- (2010) Sebastian Cancer Management and Research
- Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
- (2009) Roland E. Kontermann BIODRUGS
- Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen
- (2008) P J Conaghan et al. BRITISH JOURNAL OF CANCER
- Targeting the c-MET signaling pathway for cancer therapy
- (2008) Xiangdong Liu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More